Case Report: Diverse clinical phenotypes and treatment responses in pediatric autoimmune nodopathy: a case series
Abstract
BackgroundAutoimmune nodopathy (AN) is a recently identified category of immune-mediated peripheral neuropathy defined by circulating auto-antibodies against nodal and paranodal cell-adhesion molecules.MethodsWe retrospectively reviewed three pediatric patients with antibody-positive AN diagnosed by cell-based assay (CBA).ResultsThree male patients aged 5 years 7 months to 13 years 8 months were positive for anti-NF186 (1:32), anti-Caspr1 (1:10), and anti-NF155 (1:100) IgG, respectively. The anti-NF186-positive patient and the anti-Caspr1-positive patient presented with a CIDP/GBS-like phenotype, whereas the anti-NF155-positive patient presented with tremor, sensory ataxia, and limb weakness resembling the adult AN phenotype. These patients also had markedly elevated CSF protein and electrophysiological findings of reduced or unobtainable CMAP and SNAP amplitudes; in addition, the NF155-positive patient showed slowed motor conduction velocity. All patients received first-line therapy with IVIG and intravenous methylprednisolone pulses followed by an oral prednisone taper. Two patients responded to this regimen, and the NF155-positive patient was refractory to first-line therapy but improved after rituximab.ConclusionIn this small series, pediatric AN is heterogeneous, and antibody subtyping with clinical assessment is essential for diagnosis. First-line immunotherapy was effective in NF186- and Caspr1-positive patients, whereas the NF155-positive patient improved only after adding rituximab. Early recognition, prompt diagnosis, and timely therapeutic intervention are of paramount importance for improving the prognosis of pediatric AN.
Related
- Genetic Disruption at the CIP2A Locus Modulates T Cell Responses and Attenuates Experimental Autoimmune Encephalomyelitis
- Differential Phenotypes in Type I and Type II Pediatric Stickler Syndrome
- SIM0278, an IL-2 mutein that selectively expands regulatory T cells for the treatment of autoimmune disorders
- Clinical characteristics, treatment patterns and long-term outcomes of warm and mixed autoimmune hemolytic anemia: insights from a real-world study
- Documenting Trofinetide Treatment Phenotypes in Rett Syndrome with a Dual-LLM Consensus Pipeline
BibTeX
@article{guo2026case,
title = {{Case Report: Diverse clinical phenotypes and treatment responses in pediatric autoimmune nodopathy: a case series}},
author = {Ya Guo and Jie Song and Chao Zhang and Na Chen and Jiamin Guo},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1978921},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1978921},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Case Report: Diverse clinical phenotypes and treatment responses in pediatric autoimmune nodopathy: a case series
AU - Ya Guo
AU - Jie Song
AU - Chao Zhang
AU - Na Chen
AU - Jiamin Guo
PY - 2026
DA - 2026/10/30
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1978921
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1978921
AB - BackgroundAutoimmune nodopathy (AN) is a recently identified category of immune-mediated peripheral neuropathy defined by circulating auto-antibodies against nodal and paranodal cell-adhesion molecules.MethodsWe retrospectively reviewed three pediatric patients with antibody-positive AN diagnosed by cell-based assay (CBA).ResultsThree male patients aged 5 years 7 months to 13 years 8 months were positive for anti-NF186 (1:32), anti-Caspr1 (1:10), and anti-NF155 (1:100) IgG, respectively. The anti-NF186-positive patient and the anti-Caspr1-positive patient presented with a CIDP/GBS-like phenotype, whereas the anti-NF155-positive patient presented with tremor, sensory ataxia, and limb weakness resembling the adult AN phenotype. These patients also had markedly elevated CSF protein and electrophysiological findings of reduced or unobtainable CMAP and SNAP amplitudes; in addition, the NF155-positive patient showed slowed motor conduction velocity. All patients received first-line therapy with IVIG and intravenous methylprednisolone pulses followed by an oral prednisone taper. Two patients responded to this regimen, and the NF155-positive patient was refractory to first-line therapy but improved after rituximab.ConclusionIn this small series, pediatric AN is heterogeneous, and antibody subtyping with clinical assessment is essential for diagnosis. First-line immunotherapy was effective in NF186- and Caspr1-positive patients, whereas the NF155-positive patient improved only after adding rituximab. Early recognition, prompt diagnosis, and timely therapeutic intervention are of paramount importance for improving the prognosis of pediatric AN.
SN - 1664-3224
ER -